✓ Last verified: February 26, 2026 — Edited & verified by Angelica Bottaro for HealingMaps Editorial Staff
Known For: Spravato (esketamine) provider near Burlington offering a holistic psychiatric approach that integrates biofeedback and guided meditation with medication management.
| Review Scores | Contact clinic for reviews |
| Location | Williston, VT |
| Address | 28 Park Ave, Suite 100, Williston, VT 05495 |
| Phone | (802) 300-4628 |
| Website | onebreathvermont.org |
| Treatments | Spravato (Esketamine Nasal Spray), Psychiatric Care, Heart Rate Variability Biofeedback, Guided Meditation |
| Conditions Treated | Treatment-Resistant Depression, Depression, Anxiety |
| Cost | Contact clinic for pricing |
| Insurance | Spravato often covered by insurance |
| Clinical Lead | Jason Carriveau, PMHNP — Psychiatric Mental Health Nurse Practitioner |
HealingMaps Take: OneBreath Vermont is the Spravato provider to know in the Burlington area. Founded by Jason Carriveau, PMHNP, the practice offers esketamine nasal spray therapy from its Williston location — just minutes from Burlington, Chittenden County’s population center. What distinguishes OneBreath from a standard Spravato clinic is Jason’s holistic philosophy: alongside pharmacological treatment, the practice integrates exercise, heart rate variability biofeedback, and guided meditation into personalized care plans. This is not just a nasal spray appointment — it is a comprehensive psychiatric engagement. For patients with treatment-resistant depression in northern Vermont, the Spravato model is particularly compelling because it is the most insurance-friendly ketamine-class treatment available. OneBreath also offers free 15-minute consultations, lowering the barrier to entry for patients exploring this option.
Market Position: OneBreath Vermont is a Spravato-certified clinic in the Williston metro. Spravato (esketamine) is the FDA-approved ketamine treatment that most commercial insurance plans cover after prior authorization — unlike cash-pay IV ketamine.
Industry pricing reference. OneBreath Vermont has not published specific per-session pricing — contact the clinic directly for a quote. The calculator above shows typical metro-level cost estimates across protocols, not this clinic’s specific prices.
| Protocol | Typical Industry Cost | Offered Here |
|---|---|---|
| IV Ketamine | $350–$650/session | — |
| Spravato (esketamine) | $0–$250 copay (insured) | ✓ Yes |
| IM Ketamine | $250–$400/injection | — |
| KAP (with therapist) | $400–$1,200/session | — |
| At-home troches | $150–$300/month | — |
Sources: CDC PLACES 2023 (Vermont, state-level prevalence) · U.S. Census ACS 5 Year · HealingMaps proprietary patient inquiry data.
Behind this data: HealingMaps has analyzed 23,496 patient inquiries (Oct 2022 – Mar 2026), mapped 1,473 verified clinics across 3,142 counties, scraped 132 clinic pricing pages, and collected 658 practitioner survey responses. This snapshot reflects our multi-source methodology.
Even Spravato copays are HSA and FSA-eligible — meaning the $0–$250 per-session cost that commercial insurance leaves you can often be paid with pre-tax dollars, reducing the effective out-of-pocket by your marginal tax rate. Ask your Spravato-certified provider to document the treatment as medically necessary for your records. Source: HealingMaps 2026 Ketamine Clinic Intelligence Report — drawn from 23,496 patient inquiries and 132 clinic website analyses.
This 3-question summary is matched to the protocols and conditions OneBreath Vermont treats. Editorial responses are HealingMaps-authored, grounded in our 2026 Ketamine Clinic Intelligence Report.
Yes — OneBreath Vermont offers Spravato, which means they’re FDA REMS-certified and maintain the required two-hour in-office monitoring window after each dose. Spravato is the primary insurance-covered ketamine option for treatment-resistant depression. Worth confirming the prior-authorization timeline before booking your first session.
OneBreath Vermont treats depression via Spravato (FDA-approved for TRD). The Spravato pathway is the most likely to obtain commercial insurance coverage. TRD is typically defined as two or more prior antidepressant trials without sufficient response — patients meeting that bar are best candidates here.
Yes — OneBreath Vermont treats anxiety, including generalized anxiety, social anxiety, and panic disorder. The evidence base for ketamine in anxiety is less robust than for depression, but it can be a meaningful option for patients who haven’t responded to SSRIs or benzodiazepines. Worth asking which of their protocols they typically recommend for anxiety-primary patients.
View all REMS-certified Spravato clinics in Vermont and across the United States.
Leave a Reply